600566.SS SHH
Hubei Jumpcan Pharmaceutical Co., Ltd.
1W: +3.6%
1M: -1.0%
3M: +14.2%
YTD: -5.8%
1Y: -3.1%
3Y: +6.2%
5Y: +71.1%
¥25.63 ($3.82)
+0.76 (+3.06%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Cash Flow Trends
Operating Cash Flow
$2.2B
-37.2% ▼
5Y CAGR: +0.3%
Capital Expenditures
$174M
+42.2% ▲
5Y CAGR: -20.4%
Free Cash Flow
$2.0B
-36.7% ▼
5Y CAGR: +4.6%
Dividends Paid
$1.2B
-47.4% ▼
Buybacks
$22M
+37.8% ▲
Net Change in Cash
-$1.1B
-136.6% ▼
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $1.3B | $1.7B | $2.2B | $2.8B | $2.5B |
| Depreciation & Amort. | $281M | $294M | $309M | $304M | $308M |
| Stock-Based Comp. | $0 | $0 | $5M | $0 | $0 |
| Change in Working Capital | $171M | -$2M | $132M | $405M | -$517M |
| Other Non-Cash Items | $53M | -$115M | -$711K | -$68M | -$151M |
| Operating Cash Flow | $1.8B | $1.9B | $2.6B | $3.5B | $2.2B |
| — Investing Activities — | |||||
| Capital Expenditures | -$430M | -$248M | -$244M | -$302M | -$174M |
| Acquisitions (Net) | $36M | $51M | $53M | $8M | $0 |
| Investment Purchases | -$1.8B | -$4.8B | -$6.2B | -$4.8B | -$7.0B |
| Investment Sales | $681M | $4.4B | $4.9B | $4.7B | $5.1B |
| Other Investing | $2M | -$50M | $0 | -$82M | $695K |
| Investing Cash Flow | -$1.5B | -$673M | -$1.5B | -$476M | -$2.0B |
| — Financing Activities — | |||||
| Net Debt Issuance | -$173 | -$2M | $392M | $695M | $36M |
| Stock Repurchased | $22M | $0 | $0 | -$36M | -$22M |
| Dividends Paid | -$1.0B | -$400M | -$604M | -$811M | -$1.2B |
| Other Financing | $1.4B | $50M | $94M | -$35M | -$23M |
| Financing Cash Flow | $374M | -$361M | -$118M | -$151M | -$1.2B |
| Net Change in Cash | $674M | $860M | $1000M | $2.9B | -$1.1B |
| Cash End of Period | $3.0B | $3.8B | $4.8B | $7.7B | $6.7B |
| Free Cash Flow | $1.4B | $1.6B | $2.4B | $3.2B | $2.0B |